Gout Therapeutics Market Size & Outlook, 2026-2034

Gout Therapeutics Market Overview

The global gout therapeutics market size is estimated at USD 3.05 billion in 2025 and is projected to reach USD 5.40 billion by 2034, growing at a CAGR of 6.57% during the forecast period. The remarkable market growth is attributed to the increasing adoption of serum urate monitoring protocols, driving long-term therapy adherence and repeat prescription demand among chronic gout patients.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 41.13% share in 2025.
• The Asia Pacific region is estimated to grow at the fastest pace, with a CAGR of 8.30% during the forecast timeframe.
• Based on drug class, the xanthine oxidase inhibitors segment dominated the market with 43.78% revenue share in 2025.
• By disease type, the chronic tophaceous segment is estimated to grow at the fastest pace with a CAGR of 7.32% during 2026-2034.
• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2025 with a revenue share of 61.25%.
• The U.S. dominates the gout therapeutics market, valued at USD 1.06 billion in 2024 and reaching USD 1.12 billion in 2025.

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 3.05 billion
• 2034 Projected Market Size: USD 5.40 billion
• CAGR (2026-2034): 6.57%
• Dominating Region: North America
• Fastest Growing Region: Asia Pacific

The gout therapeutics market includes medicines used to treat and manage gout by lowering uric acid levels and controlling inflammation. It covers drug classes such as xanthine oxidase inhibitors, NSAIDs, corticosteroids, uricosurics, recombinant uricase, and interleukin-1 inhibitors. These therapies address acute attacks, intercritical phases, and chronic tophaceous gout, and are distributed through hospital pharmacies, retail drug stores, and online pharmacies to ensure broad patient access.

Market Trends

Expansion of Advanced Biologic And Recombinant Therapies For Refractory Gout

A major current trend in the gout therapeutics market is the increased focus by manufacturers on advanced biologic and recombinant uricase therapies for treatment-resistant and chronic tophaceous gout. Pharmaceutical companies are strengthening production capabilities and optimizing formulations of recombinant uricase and interleukin-1 inhibitors to improve durability, safety, and dosing convenience. This shift addresses patients who fail conventional xanthine oxidase inhibitors, expanding the treated population and driving higher-value drug adoption across specialty care settings.

Lifecycle Expansion of Established Gout Brands Through Indication And Formulation Optimization

Manufacturers extending the lifecycle of approved drugs through formulation upgrades and expanded use strategies is a key trend for market growth. For instance, Amgen, following its acquisition of Horizon Therapeutics, highlighted in its 2024 annual report a strong focus on optimizing Krystexxa utilization in chronic refractory gout through improved infusion protocols and broader physician education. This strategy enhances revenue durability without reliance on new molecular approvals.

To get more insights about this report Download Free Sample Report

Market Driver

Rising Use of Injectable Anti-Inflammatory Therapies For Severe Gout Flares

The growing reliance on injectable anti-inflammatory therapies for managing severe and hospital-treated gout flares is a key driver supporting the market growth. As acute gout cases increasingly present with high pain burden and comorbidities, physicians are favoring faster-acting injectable options. In its 2024 annual report, Novartis AG highlighted continued demand for ILARIS in inflammatory conditions, including gout flares, supporting higher utilization of premium therapies in specialty care settings.

Market Restraint

Impact of Generic Competition And Falling Prices of The Branded Gout Drug

A key restraint in the gout therapeutics market is intensifying generic competition and associated pricing pressure, which reduces revenue growth for branded therapies. Recent pricing data and manufacturer disclosures indicate that increased availability of generics like allopurinol and febuxostat has driven down average selling prices. For example, Amneal Pharmaceuticals’ 2024 quarterly reports show substantial unit share gains for generic febuxostat, squeezing margins for originator brands and constraining overall market profitability.

Market Opportunity

Expanding Therapeutic Pipelines For Acute And Chronic Gout Management

A major opportunity in the gout therapeutics market lies in developing and expanding pipelines for both acute inflammation treatments and urate-lowering agents. Manufacturers are increasingly investing in xanthine oxidase inhibitors, interleukin-1 inhibitors, and recombinant uricase therapies to address unmet patient requirements. For example, Horizon Therapeutics’ ongoing clinical programs for advanced Krystexxa formulations aim to improve efficacy and convenience, enabling broader patient coverage and creating new revenue streams across acute and chronic gout segments. Moreover, below table highlights the therapeutic pipelines for Gout in 2025.

Graph: Therapeutic pipeline in 2025

Source: Straits Research

Regional Analysis

North America dominated the gout therapeutics market in 2025, accounting for 41.13% market share. This growth is driven by the recent expansion of value-based reimbursement contracts between payers and manufacturers, which incentivize improved long term outcomes and earlier adoption of advanced treatments such as novel urate-lowering agents.

U.S. dominated the gout therapeutics industry, accounting for more than 90% share, owing to the expansion of specialty pharmacy services focused on chronic gout management, which improves access to complex therapies and adherence support. In the U.S., specialty pharmacies are increasingly coordinating with payers and clinicians to dispense advanced urate-lowering and biologic treatments, reducing barriers and enabling consistent refills for patients, thereby boosting overall therapeutic uptake.

Asia Pacific Gout Therapeutics Market Insights

Asia Pacific is emerging as a fastest growing region with a CAGR of 8.30% from 2026-2034, owing to government-supported screening and early intervention initiatives in China that integrate gout assessment into chronic disease management frameworks. Under national health programs like Healthy China 2030, larger populations are being screened for elevated serum urate and associated comorbidities, prompting earlier diagnosis and treatment initiation.

Australia’s gout therapeutics industry expanded with the rollout of culturally tailored community education and gout resource programs, especially for Aboriginal, Torres Strait Islander, and Pasifika populations, improving early diagnosis and treatment uptake. Initiatives by Arthritis Australia and partners have increased awareness and engagement, prompting higher utilization of therapeutic care among previously underserved groups.

Source: Straits Research

Europe Market Insights

Europe's gout therapeutics market growth is supported by the regional implementation of unified treatment protocols by the European Alliance of Associations for Rheumatology (EULAR), promoting consistent “treat-to-target” uric acid management across member countries. This harmonization encourages early intervention and long-term therapy adherence, improving clinical outcomes and expanding prescriptions for both urate-lowering and anti-inflammatory drugs.

The UK market for Gout therapeutics is witnessing growth due to recent focus by the NHS and UK research bodies on improving primary care gout management quality. National audits and pilot interventions shown that structured follow-up after hospital flare admissions notably increases the use of therapy within six months, enhancing treatment rates and expanding therapeutic demand across the UK healthcare system.

Latin America Market Insights

Latin America gout therapeutics market is witnessing steady growth, due to the targeted government healthcare funding in Brazil that expands access to gout medications through public programs. Brazil’s Ministry of Health has increased allocations for chronic disease care, including rheumatology services and urate-lowering drugs, improving affordability and treatment uptake among urban and rural patients, thus boosting regional market demand.

Argentina’s gout therapeutics industry is experiencing growth driven by the low referral and diagnosis rate of gout by general practitioners to rheumatologists, resulting in increased treatment demand. In Buenos Aires surveys, many gout cases are identified later or managed suboptimally before specialist care, prompting higher use of advanced therapies once diagnosed.

Middle East and Africa Market Insights

The Middle East and Africa market for gout therapeutics is expanding due to the region’s increasing investment in population-specific genetic studies that inform tailored gout treatments, in Gulf countries like Qatar and the UAE, where diverse ancestries influence drug response. Emerging genomic initiatives are enabling localized precision medicine strategies, improving clinician confidence in prescribing targeted therapies, and expanding therapeutic uptake.

The gout therapeutics market growth in South Africa is stimulated by the emergence of targeted community awareness and early detection initiatives that educate patients about gout’s symptoms and encourage earlier healthcare engagement. Local health groups and clinics have begun campaigns highlighting the link between lifestyle, hyperuricemia, and joint health, leading to increased diagnosis rates and higher demand for both acute and chronic gout treatments.

Drug Class Insights

The xanthine oxidase inhibitors segment dominated the market with a revenue share of 43.78% in 2025. This growth is attributed to the emergence of tailored dosing formulations targeted at patients with co‑existing kidney impairment, which enhances tolerability and expands eligible patient populations, accelerating segment demand.

The uricosurics segment is projected to register the fastest CAGR growth of 7.11% during the forecast period, owing to global clinical and commercial expansion of selective URAT1 inhibitors like dotinurad, which have shown superior urate-lowering efficacy and approval in new markets such as China, broadening usage beyond traditional therapies. This enhanced effectiveness and geographic rollout are attracting investment and accelerating the segment’s rapid adoption.

Source: Straits Research

Disease Type Insights

The acute segment dominated the market in 2025 with a revenue share of 43.06%. This dominance is attributed to the increasing adoption of IL‑1 inhibitors for patients with severe flares who have contraindications to NSAIDs or corticosteroids. Recent clinical evidence from Phase III trials, including firsekibart studies, demonstrates rapid flare resolution and improved safety in patients with renal impairment or cardiovascular risk, expanding acute treatment.

The chronic tophaceous segment is estimated to grow at the fastest CAGR of 7.32% during the forecast period. This growth is supported by the increasing number of patients progressing to advanced, tophi-forming gout because of delayed diagnosis or inadequate long-term urate control. This severe disease stage leads to joint deformities and functional impairment, creating higher clinical demand for gout therapeutics.

Distribution Channel Insights

The drug stores & retail pharmacies segment dominated the market in 2025 with a revenue share of 61.25%, as expanded community pharmacy chronic care programs increased patient access to gout medications, fostering higher outpatient prescription fulfillment rates compared to other channels.

The online pharmacies segment is expected to register the fastest CAGR growth during the forecast period. This growth is driven by the increasing patient preference for convenient, home-delivered gout medications, especially amid growing digital health adoption. Telemedicine integration, automatic refill services, and access to specialty urate-lowering and acute flare therapies online enable broader reach, improved adherence, and enhanced patient convenience, fueling rapid revenue growth for this distribution channel.

Competitive Landscape

The global gout therapeutics market is moderately consolidated, with several established pharmaceutical and specialty firms capturing the largest share. Leading players such as Takeda Pharmaceutical, Amgen, Novartis, GlaxoSmithKline, and Pfizer dominate through strategic initiatives including new launches, expanded indications, and targeted collaborations. These companies continuously invest in clinical development, physician education, and market access programs to enhance their competitive position and drive market growth.

Eisai Co., Ltd.: An emerging market player

Eisai Co., Ltd. emerged as a notable player in the market, particularly in the Asia-Pacific. The company is advancing its selective URAT1 inhibitor through expanded regulatory filings and strategic partnerships to broaden geographic reach. Its focused efforts on improving renal safety profiles and combination therapy potential have strengthened its position, signaling growth beyond traditional competitors and capturing increasing clinician and patient interest in targeted gout management.

List of key players in Gout Therapeutics Market

1. Takeda Pharmaceutical Company Limited
2. Amgen Inc.
3. Novartis AG
4. AstraZeneca plc
5. GlaxoSmithKline plc
6. Merck & Co., Inc.
7. Regeneron Pharmaceuticals, Inc.
8. Eisai Co., Ltd.
9. Teijin Pharma Limited
10. Pfizer Inc.
11. UCB S.A.
12. Zydus Lifesciences Limited
13. Sun Pharmaceutical Industries Limited
14. Reddy’s Laboratories Limited
15. Lupin Limited
16. Teva Pharmaceutical Industries Ltd.
17. Viatris Inc.
18. Amneal Pharmaceuticals, Inc.
19. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• December 2025: Sobi agreed to acquire Arthrosi Therapeutics, Inc., a biotechnology company focused on developing a next-generation treatment for gout. Under this agreement, SOBI expanded its product portfolio by adding pozdeutinurad (AR882).